References
- Chinese Pharmacopoeia Commission. Pharmacopoeia of People's Republic of China. China : 2010 ; 98-99.
- Chi S, Cai W, Liu P, Zhang Z, Chen X, Gao L, Qi J, Bi L, Z Chen, Qi Z. Baifuzi reduces transient ischemic brain damage through an interaction with the STREX domain of BKCa channels. Cell Death Dis. 2010 ; 1 : e13. https://doi.org/10.1038/cddis.2009.10
- Zhou L, Zhang YJ, Gao LJ, Ye Y, Qi JH, Qi Z. Structureeactivity relationship of Baifuzi-cerebrosides on BKCa channel activation. European Journal of Medicinal Chemistry. 2014 ; 75 : 301-307. https://doi.org/10.1016/j.ejmech.2014.01.007
- Coetzee T, Fujita N, Dupree J, Shi R, Andrew B, Kinuko S, Kunihiko S, Brian P. Myelination in the Absence of Galactocerebroside and Sulfatide: Normal Structure with Abnormal Function and Regional Instability. Cell. 1996 ; 86 : 209-219. https://doi.org/10.1016/S0092-8674(00)80093-8
- Ezoe T, Vanier MT, Oya Y, Popko B, Tohyama J, Matsude J, Suzuki K, Suzuki K. Biochemistry and neuropathology of mice doubly deficient in synthesis and degradation of galactosylceramide. Journal of Neurosci Research. 2000 ; 59 : 170-178. https://doi.org/10.1002/(SICI)1097-4547(20000115)59:2<170::AID-JNR3>3.0.CO;2-G
- Rao RP, Acharya JK. Sphingolipids and membrane biology as determined from genetic models. Prostaglandins Other Lipid Mediat. 2008 ; 85(1-2) : 1-16. https://doi.org/10.1016/j.prostaglandins.2007.10.002
- Jurevics H, Hostettler J, Muse ED, Sammond DW, Matsushima GK, Toews AD, Morell P. Cerebroside synthesis as a measure of the rate of remyelinationfollowing cup rizone-induced demyelination in brain. J Neurochem. 2001 ; 77 : 1067-1076. https://doi.org/10.1046/j.1471-4159.2001.00310.x
- Yanagihara T, Cumings JN. Fatty acid composition of cerebrosides and cerebroside sulphatides in cerebral oedema. Acta Neuropathologica. 1969 ; 12(1) : 62-67. https://doi.org/10.1007/BF00685311
- Qi JH, Ojika M, Sakagami YJ. Termitomycesphins A -D, Novel Neurito genic Cerebrosides from the Edible Chinese Mushroom Termitomyces albuminosus. Tetra hedron. 2000 ; 56(32) : 5835-5841. https://doi.org/10.1016/S0040-4020(00)00548-2
- Qu Y, Sun K, Gao L, Sakagami Y, Kawagishi H, Ojika M, Qi J. Termitomyce sphins G and H, Additional Cerebrosides from the Edible Chinese Mushroom Termitomyces albuminosus. Bioscience, Biotechnology, and Biochemistry. 2012 ; 76 : 791-793. https://doi.org/10.1271/bbb.110918
- Qi JH, Ojika M, Sakagami Y. Neuritogenic cerebrosides from an edible chinese mushroom. Part 2: structures of two additional termitomycesphins and activity enhancement of an inactive cerebroside by hydroxylation. Bioorganic & Medicinal Chemistry. 2001 ; 9(8) : 2171-2177. https://doi.org/10.1016/S0968-0896(01)00125-0
- Park YS, Lee SD. Evidence-based approach for herbal medicine-safety classification: Human equivalent dose-based the margin of safety. 2013 ; 17(3) : 1-12.
- Park YC, Lee SD. Introduction of evidence-based practical medicine through safety classification for herbal medicine(1). Journal of Korean Oriental Medicine. 2014 ; 35(1) : 114-123. https://doi.org/10.13048/jkm.14011
- Park YC, Lee SD. Safety classification for frequentlyused herbal medicines inducing toxic metabolites. Journal of Korean Oriental Medicine. 2015 ; 19(2) : 123-133.
- Park YC, Lee SD. Toxicity and safety classification of 4 animal medicines - Focusing on venoms from bee, snake, blister beetle and scolopendrid -. Journal of Korean Oriental Medicine. 2016 ; 20(1) : 125-144.
- Vit PJ. Approximate lethal dose versus median lethal dose in acute toxicity testing of pharmaceuticals. A retrospective study. Arch Toxicol. 1989 ; 63(4) : 343-4. https://doi.org/10.1007/BF00278650
- legislation of Ministry of food and Drug safety. Food and Drug Regulations in korea. Available from : URL : http://www.mfds.go.kr/index.do ?x=0&searchkey=notice_number&mid=1013&searchword=2015-82%C8%A3&y=0&division=&pageNo=1&seq=10128&cmd=v.
- An MJ, Heo HS, Lee JS, Son HY, Lim HO, Park GB, Lee JH, Jee JG, Park YC. Repeated Dose 90-Day Oral Toxicity Study of Dried Thermitomyces albuminosus Powder in Rats. Journal of Life Science 2016 ; 26(10) : 1153-1162. https://doi.org/10.5352/JLS.2016.26.10.1153
- FDA. Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. Rockville MD : FDA. 2005.